Preferred Label : Cyclophosphamide/Epirubicin/Prednisone/Rituximab/Vincristine Regimen;
NCIt synonyms : Rituximab-Cyclophosphamide-Epirubicin-Oncovin-Prednisone Regimen; Cyclophosphamide/Epirubicin/Prednisone/Rituximab/Vincristine; Cyclophosphamide-Epirubicin-Prednisone-Rituximab-Vincristine; Cyclophosphamide-Epirubicin-Prednisone-Rituximab-Vincristine Regimen; R-CEOP90 Regimen;
NCIt related terms : R-CEOP90 (rituximab-blit); R-CEOP90 (rituximab-pvvr); R-CEOP90 (rituximab-rixi); R-CEOP90 (rituximab-rite); R-CEOP90 (rituximab-rixa); R-CEOP90 (rituximab-abbs); R-CEOP90; R-CEOP90 (rituximab-arrx);
NCIt definition : A regimen consisting of rituximab, cyclophosphamide, epirubicin, vincristine and prednisone
that can be used to treat diffuse large B-cell lymphoma (DLBCL).;
NCI Metathesaurus CUI : CL1664732;
Codes from synonyms : 127926; 128554; 128711; 127769; 70112; 128397; 128240; 128083;
Origin ID : C181649;
UMLS CUI : C5557197;
Semantic type(s)
chemotherapy_regimen_has_component
concept_is_in_subset